The 4th Molnupiravir drug is licensed in Vietnam

Drug Molnupiravir Stella 200 mg; Molnupiravir 200mg content, hard capsule form, shelf life 6 months, box of 4 blisters x 10 tablets. Registration number is SKU: VD3-174-22 of Stellapharm Joint Venture Company Limited – Branch 1 (Stellapharm JV Co., Ltd. – Branch 1) production and registration.

The licensing for this drug is valid for 3 years from the date of signing the decision.

Thus, up to now, there have been 4 drugs Molnupiravir – treatment COVID-19 domestic production is licensed for circulation. In February 2022, the Drug Administration of Vietnam also licensed 3 other Molnupiravir drugs, which are Molravir 400: Molnupiravir 400 mg content, hard capsule form, shelf life of 6 months, issued by Boston Vietnam Pharmaceutical Joint Stock Company South production.

Movinavir with 200 mg of Molnupiravir, hard capsule form, shelf life of 6 months, manufactured by Mekophar Pharmaceutical Joint Stock Company. Molnuporavir Stella 400: content of 400 mg Molnupiravir, hard capsule form, shelf life of 8 months, manufactured by Stellapharm Joint Venture Company Limited – branch 1.

After licensing the 4th Molnupiravir drug, the Drug Administration of Vietnam requires manufacturing facilities and registration of manufactured drugs according to the dossiers and documents registered with the Ministry of Health. Units need to coordinate with treatment facilities to strictly comply with current regulations on prescription drugs, monitor safety, effectiveness, and unwanted effects of drugs on Vietnamese people, and synthesize and report according to the law.

The Drug Administration also requires units to strengthen monitoring, supervision and detection of cases of adverse drug reactions (if any), send reports to the National Center for Drug Information and follow Adverse drug reaction monitoring (Hanoi) or Regional Center for drug information and adverse drug reaction monitoring (HCMC) according to regulations.